Daily Cardiology Research Analysis
Analyzed 65 papers and selected 3 impactful papers.
Summary
Today’s top cardiology papers span translational cardio-oncology, vascular-lymphatic mechanisms in diabetes-aggravated coronary disease, and perfusion physiology in DCD heart transplantation. A dual-action small molecule (ICG-001) mitigates doxorubicin cardiotoxicity while enhancing tumor cytotoxicity, impaired pericoronary lymphangiogenesis via attenuated IGF1–IGF1R signaling emerges as a target in diabetic CAD, and minimizing intraoperative oxygen debt may reduce early graft dysfunction after prolonged warm ischemia.
Research Themes
- Cardio-oncology: dual-action cardioprotection with preserved antitumor efficacy
- Metabolic-lymphatic crosstalk in diabetic coronary atherosclerosis
- Goal-directed perfusion physiology in DCD heart transplantation
Selected Articles
1. ICG-001 Provides Cardioprotection Against Doxorubicin-Induced Cardiotoxicity and Enhances Cancer Cytotoxicity.
Using patient-derived iPSC-cardiomyocytes and murine models, ICG-001 prevented doxorubicin cardiotoxicity comparably to dexrazoxane, while simultaneously increasing cytotoxicity against cancer cells. Mechanistically, it protected cardiomyocyte mitochondria via DPR1 inhibition and suppressed tumor growth through Wnt signaling repression, offering a rare dual-benefit profile.
Impact: This study identifies a single agent that both mitigates anthracycline cardiotoxicity and enhances antitumor activity, addressing a central trade-off in cardio-oncology. The mechanistic clarity across multiple systems strengthens its translational potential.
Clinical Implications: If validated clinically, ICG-001 could be integrated as an adjunct to doxorubicin to reduce cardiotoxicity without sacrificing (and potentially improving) oncologic efficacy, particularly in high-risk patients.
Key Findings
- ICG-001 suppressed doxorubicin-induced cardiotoxicity in human iPSC-cardiomyocytes and in mice, comparable to dexrazoxane.
- Unlike dexrazoxane, ICG-001 increased cytotoxicity in cancer cells, improving antitumor activity.
- Mechanisms diverged by tissue: DPR1 inhibition preserved cardiomyocyte mitochondrial integrity, while Wnt signaling repression mediated antitumor effects.
Methodological Strengths
- Translational approach spanning human iPSC-cardiomyocytes and in vivo mouse models
- Mechanistic dissection demonstrating pathway-specific actions (DPR1 vs Wnt)
Limitations
- Preclinical study without human clinical outcomes
- Breadth of tumor models and dose–response generalizability are not fully detailed
Future Directions: Proceed to phase I safety and dose-finding in patients receiving anthracyclines, with parallel cardio-oncology endpoints (troponin/GLS/CMR) and tumor response, and evaluate drug–drug interactions with standard regimens.
Doxorubicin is effective against cancer but can cause doxorubicin-induced cardiotoxicity (DCT). Drug discovery efforts against DCT are hampered by the need to balance cardioprotection and cancer control. This study demonstrates that ICG-001 suppressed DCT in patient-derived human induced pluripotent stem cell-derived cardiomyocytes in vitro and in mice in vivo, comparable to conventional treatment, dexrazoxane. Unlike dexrazoxane, ICG-001 was cytotoxic to cancer cells. Mechanistically, ICG-001 protected the mitochondria in card
2. Impaired lymphangiogenesis in pericoronary adipose tissue correlates with diabetes-aggravated coronary atherosclerosis.
In 160 prospectively enrolled surgical patients, pericoronary adipose tissue from CAD—especially DM-CAD—showed reduced lymphatic vessel density correlating with adipocyte hypertrophy and CAD severity. snRNA-seq identified weakened IGF1–IGF1R signaling between epicardial adipocytes and lymphatic endothelial cells; recombinant IGF1 rescued lymphangiogenesis under diabetic conditions.
Impact: This study uncovers a novel adipocyte–lymphatic endothelial signaling axis (IGF1–IGF1R) in human pericoronary fat that links diabetes to aggravated coronary atherosclerosis, revealing a potentially druggable pathway.
Clinical Implications: PCAT lymphatic density may serve as a biomarker of CAD severity in diabetes, and targeting IGF1–IGF1R signaling to enhance lymphangiogenesis could be explored as a therapeutic strategy.
Key Findings
- CAD, particularly with diabetes, exhibited reduced PCAT lymphatic vessel density, increased EpAT volume, adipocyte hypertrophy, and macrophage infiltration.
- Lymphatic vessel density inversely correlated with adipocyte size and CAD severity; DM-CAD patients had worse prognosis and higher readmission rates.
- snRNA-seq revealed attenuated IGF1–IGF1R signaling between adipocytes and LECs; recombinant IGF1 enhanced LEC proliferation, migration, and tube formation under diabetic conditions.
Methodological Strengths
- Prospective human tissue study with imaging, histopathology, and clinical phenotyping
- Single-nucleus RNA-seq coupled with in vitro diabetic models for mechanistic validation
Limitations
- Observational design limits causal inference between lymphatic impairment and CAD progression
- Subgroup sample sizes and single-country timeframe may limit generalizability
Future Directions: Validate PCAT lymphatic metrics as prognostic biomarkers and test IGF1–IGF1R pathway modulation (e.g., IGF1 analogs) in early-phase clinical trials targeting diabetic CAD.
BACKGROUND: Epicardial adipose tissue (EpAT), particularly pericoronary adipose tissue (PCAT), plays a crucial role in diabetes mellitus (DM)-aggravated coronary artery disease (CAD). Emerging evidence suggests that dysfunction of the arterial lymphatic network contributes to atherosclerosis progression. Our study aimed to investigate whether lymphatic vessel impairment in PCAT (a type of EpAT) is involved in DM-related CAD and to explore its underlying molecular mechanisms. METHODS: We prospectively enrolled patients undergoing heart valve surgery (control [CTRL] group) and coronary artery bypass grafting surgery (CAD group) between February 2024 and March 2025. EpAT volume (EpATv) and SYNTAX scores were assessed, and human PCAT samples were performed with pathological staining. Single-nucleus RNA sequencing (snRNA-seq) was employed to characterize intercellular communication between epicardial adipocytes and lymphatic endothelial cells (LECs). In vitro diabetic models of human adipocytes and LECs were established using palmitic acid (PA) and high concentration glucose (HG) to verify intercellular signaling. RESULTS: Of a total of 160 patients enrolled (113 males), 48 were controls and 112 were CAD patients (44 with DM). CAD patients, particularly those with DM, showed increased EpATv, adipocyte size, macrophage infiltration, and reduced lymphatic vessel density. Lymphatic vessel density was inversely correlated with both adipocyte size and CAD severity. CAD patients with DM also had worse prognosis and higher readmission rates. snRNA-seq analysis revealed significantly attenuated IGF1-IGF1R signaling between epicardial adipocytes and LECs in the PCAT of CAD patients with DM. Recombinant IGF1 effectively enhanced LEC proliferation, migration, and tube formation under diabetic conditions, whereas the IGF1R antagonist impeded these protective effects. CONCLUSIONS: Our findings demonstrate that attenuated IGF1-IGF1R signaling between epicardial adipocytes and LECs may contribute to lymphatic impairment in PCAT, which is associated with CAD progression in DM. Our work may represent a novel potential therapeutic target for CAD patients with DM. RESEARCH INSIGHTS: What is currently known about this topic?Lymphatic vessels play a crucial role in mediating the progression of atherosclerosis. Epicardial adipose tissue (EpAT) acts as critical anatomical and functional link coupling diabetes mellitus (DM) and coronary artery disease (CAD). Adipocytes are involved in the regulation of lymphatic endothelial cell proliferation and lymphangiogenesis.What is the key research question?Whether impaired lymphatic vessels in pericoronary adipose tissue (PCAT, a type of EpAT) were involved in the pathological development of DM-related CAD.What is new?DM-aggravated CAD is associated with reduced lymphatic vessel density within PCAT. It identifies a novel intercellular signaling interaction between epicardial adipocytes and lymphatic endothelial cells in modulating lymphangiogenesis.How might this study influence clinical practice?Enhancing lymphangiogenesis through modulation of IGF1-IGF1R signaling pathway may offer new strategies for improving cardiovascular outcomes. Additionally, lymphatic vessel density in PCAT may serve as a biomarker for CAD severity and progression. This work highlights a novel potential therapeutic target for CAD patients with DM.
3. Intraoperative Oxygen Debt is Associated with Early Clinical Outcomes After Prolonged Asystolic Warm Ischemia Time in Donation After Circulatory Death Heart Transplantation.
In 112 DCD heart transplants supported by TA-NRP, higher intraoperative oxygen extraction burden correlated with severe PGD and early mortality, especially when AWIT was ≥10 minutes. Lower O2ER burden (≤70 minutes >20%) reduced the odds of severe PGD (OR 0.09) and composite adverse outcomes (OR 0.13), supporting goal-directed perfusion strategies to minimize oxygen debt.
Impact: Introduces a physiologic, real-time perfusion metric (O2ER) associated with early DCD heart transplant outcomes, offering a modifiable intraoperative target, particularly for prolonged warm ischemia.
Clinical Implications: Incorporating O2ER-guided goal-directed perfusion may mitigate risk in DCD hearts with prolonged AWIT and could be integrated into intraoperative management protocols and donor–recipient selection strategies.
Key Findings
- High intraoperative O2ER burden (>20% for >70 minutes) was associated with higher rates of severe PGD and 30- and 90-day mortality, especially in AWIT ≥10 minutes.
- Within prolonged-AWIT recipients, lower O2ER burden reduced odds of severe PGD (OR 0.09, 95% CI 0.07–0.87) and the composite morbidity–mortality endpoint (OR 0.13, 95% CI 0.07–0.54).
- Dose–response modeling showed increasing O2ER burden aligned with worsening outcomes, supporting O2ER as a modifiable intraoperative risk metric.
Methodological Strengths
- High-resolution minute-by-minute CPB perfusion data with physiologic O2ER computation
- Advanced causal inference methods (IPW and Firth-penalized logistic regression) with dose–response assessment
Limitations
- Retrospective single-program analysis may limit generalizability and is susceptible to residual confounding
- No external validation; thresholds for O2ER burden require prospective confirmation
Future Directions: Prospective, multicenter trials testing O2ER-guided perfusion targets in DCD heart transplantation, with predefined thresholds and integration into donor selection/recipient management algorithms.
BACKGROUND: Donation-after-circulatory-death (DCD) heart transplantation remains constrained by warm ischemic injury, particularly the asystole-to-reperfusion interval (AWIT). We evaluated whether intraoperative oxygen debt-summarized by oxygen extraction ratio (O₂ER), a physiologic substrate for goal-directed perfusion (GDP)-is associated with early outcomes and modifies risk among prolonged-AWIT grafts. METHODS: Adult DCD heart transplant recipients recovered using thoracoabdominal normothermic regional perfusion (TA-NRP) from October 2021 to February 2025 were retrospectively analyzed. O₂ER (VO₂i/DO₂i) was computed from minute-by-minute cardiopulmonary bypass (CPB) records; burden was quantified as cumulative minutes with O₂ER >20% and dichotomized at the cohort mean (≤70 vs >70 minutes). Patients were stratified by AWIT (<10 vs ≥10 minutes). Outcomes included severe primary graft dysfunction (PGD), 90-day mortality, and a composite morbidity-mortality endpoint. Associations were estimated using inverse-probability weighting and weighted Firth-penalized logistic regression with dose-response modeling. RESULTS: Among 112 recipients, 40 (36%) had prolonged AWIT. The prolonged-AWIT/high-O₂ER group (n=18) had the highest incidence of severe PGD (22%), 30-day mortality (17%), and 90-day mortality (22%). Within prolonged-AWIT recipients, lower O₂ER burden (≤70 minutes) was associated with reduced odds of severe PGD (OR 0.09, 95% CI 0.07-0.87) and the composite endpoint (OR 0.13, 95% CI 0.07-0.54). Continuous modeling demonstrated consistent directional associations between increasing O₂ER burden and adverse outcomes. CONCLUSIONS: Intraoperative O₂ER burden was jointly associated with early graft dysfunction and mortality, particularly in the setting of prolonged AWIT. These hypothesis-generating findings support the potential role for GDP strategies that minimize intraoperative oxygen debt to mitigate warm ischemic vulnerability in DCD heart transplantation.